Brief: H. Lundbeck Announces Positive Results From RESOLUTION Trial
Dec 3 (Reuters) - H Lundbeck A/S HLUNb.CO :
* EFFICACY OF VYEPTI HIGHLIGHTED BY NEW CLINICAL TRIAL
RESULTS IN
SEVERE MIGRAINE
* - VYEPTI MET PRIMARY ENDPOINT, SHOWING STATISTICALLY
SIGNIFICANT
GREATER MONTHLY MIGRAINE DAY (MMD) REDUCTIONS
Source text: ID:nWkr6NsSCk
Further company coverage: HLUNb.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on H Lundbeck A/S
See all newsUBS upgrades Lundbeck to 'buy' on high epilepsy drug conviction
DB downgrades Lundbeck to 'sell' on Rexulti patent cliff risk
Europe Research Roundup: ASM International, Michelin, Nokian Renkaat
Europe Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program